On-body Drug Delivery Devices - Intellectual Property Landscape: Focus on Popular/Relevant Prior Art Search Expressions, Patent Valuation, Pockets of Innovation/White Spaces, and Key Applicant Profiles

Overview

Chronic diseases, such as diabetes, arthritis, hypertension and cancer, are considered among the leading causes of death, worldwide. In fact, a recent study revealed that the global failure to control the steady rise in preventable risk factors associated with the aforementioned conditions rendered populations vulnerable to COVID-19. Although there are several national and global-level initiatives focused on educating the masses on prevention and promote healthy living, individuals living with a chronic medical condition are required to medicate on a frequent basis - which is often multiple times in a single day. Lack of adherence to prescribed medication regimens (due to various reasons) and high cost of treatment (a significant share of which stems from non-compliance to treatment), are the major contributing factors to the associated burden on patients and the healthcare system. However, modern therapy administration technology, such as wearable and implantable drug delivery solutions, allows patients to effectively deal with several of the areas of concern related to therapy adherence and treatment costs. 

With provisions to adhere to, or be implanted in the body, this advanced category of drug delivery solutions are known to (1) enable patients to self-medicate (thereby, saving on routine hospital visit fees), (2) effectively reduce the number of needle-pricks in case of patients who are required to medicate multiple times in a day, (3) administer large volumes (more than 2 mL) of therapeutic formulations over an extended period of time, and (4) improve compliance to therapeutic regimens (some devices include provisions for monitoring/tracking dosing). The advantages of on-body drug delivery devices are numerous; consequently, the demand for such devices is also high and growing, which is projected to grow to a USD 600 million market by 2030. Within such a lucrative and rapidly evolving market it is imperative for innovators and other stakeholders (including interested investors) to regularly track the growing intellectual capital. In this context, we have analyzed the intellectual property landscape related to on-body (wearable and implantable) drug delivery solutions, and developed independent opinions on both historical and recent trends, and other key attributes of the innovation in this upcoming field of medical technology.

Scope of the Report

The “On-body Drug Delivery Devices - Intellectual Property Landscape” report features an extensive study of the historical and current collection of granted patents, patent applications and affiliated documents associated with modern wearable/implantable therapy administration solutions. The information in this report has been presented across two deliverables, namely an Excel sheet, featuring an interactive dashboard, and a PowerPoint presentation, summarizing the ongoing activity in this domain, and key insights drawn from the available data. 

The report features the following details:

Overall Intellectual Property Landscape

An in-depth analysis of the various patents and affiliated IP documents that have been published related to technologies and methods associated with wearable/implantable drug delivery devices, featuring key insights from historical and recent trends

Popular/Relevant Prior Art Search Expressions

An examination of IP literature, identifying key words and phrases that are used to describe innovations in portable, large volume drug dispensing solutions, including information on historical usage in IP filings, key affiliated terms (which can be used to further identify similar innovations), and other related trends

Patent Valuation Analysis

A competitive benchmarking and valuation analysis, taking into account important IP associated parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (taking into consideration regional GDP), where the IP application was filed

Pockets of Innovation and White Spaces

An analysis of the CPC symbols and affiliated families, to identify historical and existing pockets of innovation, featuring an insightful discussion on the prevalent white spaces in this area of research

Company Profiles

Detailed profiles of the key players that have the maximum number of IP publication in the period between 2001-2021, including overview of the company, financial information (if available), and its proprietary IP related trends
Deiverable Outlines

Excel Deliverable

• The first section of the spreadsheet features details on how the input data for this project was collated, including the search strings used to query the lens.org patent database and noise removal criteria.
• The second section of the deliverable is a summary MS Excel dashboard, offering a detailed graphical perspective of the intellectual property landscape of on-body drug delivery solutions, highlighting trends key patent/patent application publication trends, CPC symbol usage over time and intellectual capital-related publication trends of key applicants that are engaged in this industry 
• The third section of the spreadsheet is an elaborate table, which features a long list of all the intellectual capital (namely granted patents, patent applications, limited patents, amended patents, abstracts, statutory invention registration and search reports) related publications, for which the relevant details are available in the public domain. 
• The next section of the deliverable includes an analysis of the key CPC symbols, highlighting usage trends (since 2001) related to the top CPC symbol and CPC families, used by innovators in this field of medical technology to describe their respective products/technologies/methods of use.
• The final section of the deliverable includes an analysis of the key applicants that have published the various types of intellectual property documents that have been considered in this report. It also features another table, which includes information on the top 25 applicants, based on the number of intellectual capital related publications, in the period 2001-2021 

PowerPoint Deliverable

• The first part of this deliverable features an executive summary of the key insights generated from analyzing the intellectual property landscape associated with on-body drug delivery devices.
• The next part provides important details related to on-body drug delivery devices, including key product related definitions, advantages of the technology and the methodology used (in this project) to query the public database, lens.org, for information on the published intellectual capital related to this innovation.
• The third section of the deliverable includes charts and figures describing the overall intellectual property landscape of on-body drug delivery devices and affiliated technologies/methods of use.
• The next section of the deliverable includes charts and figures describing the intellectual property landscape of on-body drug delivery devices and affiliated technologies/methods of use, since 2001.
• The subsequent section features insights from a detailed analysis of the titles of patent/patent applications related to wearable and implantable drug delivery solutions.It includes multiple word clouds, which help identify the most important keywords that can be used for prior art research specific to this field.
• The sixth section provides our independent views on the relative valuation of the intellectual property related to on-body drug delivery devices, taking into account important associated parameters, such as type of document, year of application, time to expiry, number of citations and jurisdiction (taking into consideration regional GDP), where the IP application was filed.
• The next section features an analysis of the CPC symbols and affiliated families, to identify historical and existing pockets of innovation, and also includes an insightful discussion on the prevalent white spaces in this area of research.
• Finally, it includes profiles of the companies having the maximum number of intellectual capital related publication in the period between 2001-2021, including overview of the company, financial information (if available), and its proprietary intellectual property publication related trends.